Winning for the third time in a row! Medicilon won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year"

On April 30, the highly anticipated "The 4th Pharmaceutical Innovation Award" event came to a successful conclusion. At this event gathering industry elites, Medicilon USA Corp. (Medicilon) stood out with its cutting-edge innovative technology and excellent service capabilities, and won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year".

Winning this honor for the third time undoubtedly represents a high recognition and affirmation of Medicilon's twenty years of empowerment in drug innovation!

The "Pharmaceutical Innovation Award" is organized by the Securities Times in 2020, aiming to promote the improvement of drug innovation capabilities by selecting outstanding drug innovation projects, outstanding companies and outstanding figures in China. The selection expert committee conducts selection based on the "Finance - Innovative Drug Index" database, drug evaluation and other related factors. The event attracted more than 100 pharmaceutical companies, innovative drug R&D companies, and medical service companies to participate. It has garnered widespread attention from industry experts and the academic community.

Deeply rooted in the genes of innovation, accumulating the driving force for development. Since its establishment twenty years ago, Medicilon has consistently adhered to driving comprehensive innovation through technological innovation, continuously investing in research and development resources, strengthening technological platform construction, and has grown into a leading one-stop preclinical research and development service platform in China. In 2023, Medicilon has been even more determined, adding several core technological platforms, such as the oligonucleotide drug development pilot platform, gene toxicity impurity assessment platform, and organoid platform based on iPS sources, further improving the one-stop innovative drug preclinical research and development service platform based on AI technology. At the same time, Medicilon has also strengthened the construction of the preclinical safety evaluation platform for traditional Chinese medicine, establishing platforms such as liver live puncture, muscle biopsy, and intrathecal injection platforms, providing solid support for early screening, druggability, and IND filing.

After twenty years of continuous hard work, Medicilon’s innovation tree has yielded fruitful results and is full of “fruits of empowerment”. Since 2015, Medicilon has been involved in the research and development of 421 new drugs and generic drug projects, which have been approved by the CFDA/NMPA, the US FDA, and the Australian TGA to enter clinical trials, accelerating the R&D process of new drug development for clients. As of the end of 2023, Medicilon has served 50+ ADC clients, among which 24 have been approved by the NMPA and FDA and entered the clinical trial stage. It has also served 40+ oligonucleotide clients and 3+ PROTAC-related clients, and has assisted in the approval of clinical trials for 8 GLP-1 related drugs.

In the future, Medicilon will always stand at the forefront of innovation and new drug development in the biopharmaceutical industry, actively building a more complete, efficient, and high-quality innovative technology service platform to contribute to the global development of drug innovation!

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客